The Crown Princess of Norway is awaiting a lung transplant, it was announced today by the Norwegian royal household. Princess Mette-Marit, 50, has been suffering from chronic pulmonary fibrosis, a condition that progressively damages lung tissue and impairs breathing. The procedure, which is not available in Norway due to a lack of specialist centres, will be performed in the United Kingdom, where advances in transplant medicine have positioned British hospitals at the forefront of international treatment.
The decision to transfer the Crown Princess to a British facility underscores the UK’s reputation in complex thoracic surgery. The Royal Brompton and Harefield hospitals, both part of Guy’s and St Thomas’ NHS Foundation Trust, are among the world’s leading centres for lung transplantation. Their expertise in managing rare and high-risk cases, combined with robust post-operative care protocols, has resulted in survival rates that exceed global averages.
Princess Mette-Marit’s condition was first disclosed in 2018, when she revealed her diagnosis of pulmonary fibrosis. The disease, which causes progressive scarring of the lungs, has no known cure. Transplantation remains the only definitive treatment for advanced stages. The Norwegian royal household stated that the Crown Princess’s health had deteriorated to a point where intervention was necessary, but declined to provide further clinical details, citing medical confidentiality.
The procedure is expected to take place within weeks, pending the availability of a suitable donor. The waiting time for lung transplants in the UK varies; according to NHS Blood and Transplant, the median wait for a lung transplant in 2023 was 215 days. However, patients with urgent status, determined by clinical urgency and compatibility, are prioritised.
British transplant innovation has been driven by several factors. The NHS’s centralised organ allocation system, which matches donors to recipients based on medical need and tissue compatibility, has been refined over decades. Moreover, UK surgeons have pioneered techniques such as ex vivo lung perfusion, which allows damaged donor lungs to be reconditioned outside the body, increasing the pool of viable organs. This method, used at Harefield Hospital, has expanded transplant opportunities for patients who would otherwise remain on waiting lists.
The Crown Princess’s case has drawn attention to the broader issue of organ donation rates. Norway, like many European countries, relies on a presumed consent system introduced in 1996. Yet demand for lungs far exceeds supply, with only 25 lung transplants performed in Norway in 2022. The UK, by contrast, conducted 168 lung transplants in the same period, reflecting a larger population but also a higher per capita rate of donation.
The Norwegian royal family has requested privacy during this time. Crown Prince Haakon, her husband, has cancelled all official engagements to be at her side. The Crown Princess’s children, including stepson Marius Borg Høiby and her two younger children with the Crown Prince, are expected to remain in Norway to maintain continuity of their schooling.
British medical authorities have expressed confidence in the planned operation. Professor Helen Spencer, a consultant in respiratory medicine at Royal Brompton, said in a statement: “Our team has deep experience in managing complex cases and we are fully prepared to provide the highest standard of care.” No further details of the surgical team have been released.
This is not the first time a European royal has sought treatment in the UK. In 2021, King Juan Carlos of Spain received medical care in London for a hip operation. The UK’s National Health Service, despite facing its own challenges of waiting lists and funding pressures, continues to attract international patients for specialist procedures, often through private arrangements.
The Crown Princess’s condition is not believed to be hereditary. Pulmonary fibrosis can result from environmental factors, autoimmune diseases, or be idiopathic. Princess Mette-Marit has been a patron of the Norwegian Heart and Lung Patient Organisation and has spoken openly about her illness, aiming to reduce stigma and raise awareness about chronic respiratory conditions.
As the Crown Princess enters this critical phase of treatment, the focus remains on clinical outcomes. The procedure, though routine in specialist centres, carries significant risks including rejection, infection, and the lifelong need for immunosuppressive drugs. British transplant teams are accustomed to managing these challenges, and the bilateral relationship between Norway and the UK ensures close coordination throughout the process.
